

#### Terms & Conditions

Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at <http://pubs.acs.org/page/copyright/permissions.html>



ACS Publications

MOST TRUSTED. MOST CITED. MOST READ.

# SUPPLEMENTARY MATERIAL

## Conformationally Unbiased Macrocyclization Reactions by Ring Closing Metathesis

Alois Fürstner\* and Klaus Langemann

Max-Planck-Institut für Kohlenforschung

Kaiser-Wilhelm-Platz 1, D-45470 Mülheim/Ruhr, Germany

**General.** All reactions were carried out under Ar using Schlenk techniques.  $\text{Cl}_2\text{Ru}(\text{PCy}_3)_2=\text{CHCH}=\text{CPh}_2$  (**1**) was prepared from 3,3-diphenylcyclopropene according to the literature procedure.<sup>3</sup> **Commercially available reagents:** 10-undecen-1-ol, 5-hexenoic acid, 10-undecenoyl chloride, 5-hexen-1-ol, 4-(N,N-dimethyl)-amino-pyridine (DMAP), (Fluka); 7-octene-1-ol, Pd on charcoal (5%), (Aldrich). **Other substrates:** Racemic 2-methyl-hept-6-en-1-ol (**19**) was prepared from 2-methyl-6-heptenoic acid by reduction with  $\text{LiAlH}_4$  according to Snider, B. B.; Allentoft, A. J.; Walner, M. B. *Tetrahedron* **1990**, *46*, 8031 - 8042. (*R*)-2-methyl-hept-6-en-1-ol (+)-(**19**) was obtained upon alkylation of (2*S*)-N-propionylbornane-10,2-sultam (**17**)<sup>13</sup> with 1-iodo-5-pentene and subsequent reduction of the resulting product **18**.  $\text{CH}_2\text{Cl}_2$  was dried by distillation from  $\text{CaH}_2$  and was stored under Ar. **Flash Chromatography:** Merck silica gel 60 (230 - 400 mesh) with n-hexane/ethyl acetate in various proportions as eluent. **Instrumental Analyses:** NMR: Spectra were recorded on a Bruker AC 200 at 200.2 MHz ( $^1\text{H}$ ) and 50.3 MHz ( $^{13}\text{C}$ ) in  $\text{CDCl}_3$ . Chemical shifts are listed downfield in ppm relative to tetramethylsilane. Coupling

constants (J) are given in Hz. IR: Nicolet FT - 7199, wavenumbers in  $\text{cm}^{-1}$ . MS: Varian CH - 5 (70 eV). HR-MS: Finnigan MAT SSQ 7000 (70 eV). Optical rotation measurements: Jasco DIP - 360 polarimeter in  $\text{CH}_2\text{Cl}_2$  using a 5 cm path length quartz cell at the temperature stated.

**Preparation of Terminally Unsaturated Esters. Representative Procedure.** A solution of hex-5-en-1-ol (475 mg, 4.75 mmol) and DMAP (610 mg, 5 mmol) in  $\text{CH}_2\text{Cl}_2$  (15 mL) was added dropwise to a stirred solution of 10-undecenoyl chloride (810 mg, 4 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 mL) at  $0^\circ\text{C}$ . Stirring was continued for 4 h at room temperature. The reaction mixture was filtered through a short pad of silica, the solvent was evaporated and the product purified by flash chromatography with hexane/ethyl acetate (50:1  $\rightarrow$  20:1) as eluent. Ester **3** was obtained as a colorless syrup (1.002 g, 94 %).

**Macrocyclization Reactions via Ring Closing Metathesis (RCM). Representative Procedure.** A solution of substrate **3** (298 mg, 1.12 mmol) in  $\text{CH}_2\text{Cl}_2$  (100 mL) and a solution of the ruthenium carbene **1** (50 mg, 0.054 mmol, 5 mol%) in  $\text{CH}_2\text{Cl}_2$  (100 mL) were simultaneously added dropwise over a period of 24 h to  $\text{CH}_2\text{Cl}_2$  (50 mL) at room temperature. After stirring for another 6 h, the solvent was removed *in vacuo* and the residue was purified by flash column chromatography with n-hexane/ethyl acetate (100:1) as eluent to afford lactone **4** as a colorless syrup (219 mg, 79 %).

**Hydrogenation of Unsaturated Lactones. Representative Procedure.** Pd on charcoal (5% w/w, 35 mg) was added to a solution of compound **4** (135 mg, 0.57 mmol) in ethyl acetate (10 mL). The mixture was stirred under  $\text{H}_2$  (1 atm) at room temperature for 40 min. The Pd catalyst was filtered off through a short pad of silica

and was washed several times with ethyl acetate. Removal of the solvent *in vacuo* afforded Exaltolide (**2**) in analytically pure form (130 mg, 95 %).

**Hex-5-en-1-yl undec-10-enoate (3)**. Colorless syrup.  $^1\text{H}$  NMR: 1.30 - 1.72 (m, 16H), 1.98 - 2.16 (m, 4H), 2.29 (t, 2H,  $J = 7.7$ ), 4.07 (t, 2H,  $J = 6.6$ ), 4.91 - 5.05 (m, 4H), 5.70 - 5.88 (m, 2H).  $^{13}\text{C}$  NMR: 25.0, 25.2, 28.1, 28.9, 29.1, 29.1, 29.3, 29.4, 33.3, 33.8, 34.4, 64.1, 114.1, 114.9, 138.3, 139.1, 173.9. IR: 3077, 2976, 2928, 2856, 1738, 1641, 1461, 1441, 1417, 1390, 1354, 1240, 1172, 1116, 993, 910. MS  $m/z$  (rel. intensity): 266 ( $\text{M}^+$ , 1), 166 (7), 148 (12), 96 (11), 82 (100).

**Pentadec-10-en-15-olide (4)**. Colorless syrup. Ratio of isomers ~ 46 : 54.  $^1\text{H}$  NMR: 1.30 - 1.49 (m, 10H), 1.54 - 1.72 (m, 4H), 2.00 - 2.10 (m, 4H), 2.29 - 2.37 (m, 2H), 4.07 - 4.18 (m, 2H), 5.28 - 5.45 (m, 2H).  $^{13}\text{C}$  NMR: 25.2, 25.4, 26.5, 26.6, 27.1, 27.2, 27.6, 27.9, 28.0, 28.1, 28.2, 28.3, 28.4, 28.4, 29.1, 32.0, 33.9, 34.7, 64.0, 64.1, 129.6, 130.1, 130.4, 131.7, 173.9. IR: 3000, 2928, 2856, 1736, 1461, 1385, 1346, 1252, 1234, 1168, 1152, 1113, 1085, 1024, 969, 719. MS  $m/z$  (rel. intensity): 238 ( $\text{M}^+$ , 20), 210 (18), 109 (17), 96 (49), 82 (100), 67 (64), 55 (64). HR-MS *calcd.* for  $\text{C}_{15}\text{H}_{26}\text{O}_2$ : 238.1933, *found*: 238.1920.

**Undec-10-en-1-yl hex-5-enoate (5)**. Colorless syrup.  $^1\text{H}$  NMR: 1.30 - 1.37 (m, 12H), 1.55 - 1.80 (m, 4H), 1.99 - 2.16 (m, 4H), 2.31 (t, 2H,  $J = 7.4$ ), 4.06 (t, 2H,  $J = 6.7$ ), 4.90 - 5.07 (m, 4H), 5.68 - 5.87 (m, 2H).  $^{13}\text{C}$  NMR: 24.1, 25.9, 28.7, 28.9, 29.1, 29.2, 29.4, 29.5, 33.1, 33.6, 33.8, 64.4, 114.1, 115.2, 137.6, 139.1, 173.6. IR: 3078, 2928, 2855, 1738, 1641, 1461, 1244, 1171, 993, 911. MS  $m/z$  (rel. intensity): 266 ( $\text{M}^+$ , 2), 154 (18), 115 (47), 96 (48), 82 (50), 69 (100), 55 (97).

**Pentadec-5-en-15-olide (6).** Colorless syrup. (*E*) : (*Z*) ~ 77 : 23. <sup>1</sup>H NMR: 1.24 - 1.28 (m, 12H), 1.55 - 1.71 (m, 4H), 1.92 - 2.09 (m, 4H), 2.28 (t, 2H, J = 7.2), 4.05 (t, 1.7 H, J = 5.3), 4.08 (t, 0.3 H, J = 5.2), 5.16 - 5.36 (m, 2H). <sup>13</sup>C NMR: (*E*)-isomer: 22.5, 25.0, 25.2, 25.9, 26.3, 26.8, 26.9, 27.3, 29.7, 31.0, 31.1, 63.5, 128.5, 131.2, 172.6. (*Z*)-isomer (resolved signals): 24.4, 24.5, 25.1, 25.2, 25.5, 25.8, 25.9, 26.8, 33.1, 63.3, 127.8, 130.0, 172.7. IR: 3005, 2934, 2850, 1738, 1452, 1350, 1254, 1240, 1170, 969, 714. MS *m/z* (rel. intensity): 238 (M<sup>+</sup>, 48), 126 (26), 110 (18), 96 (55), 82 (100), 67 (83). HR-MS *calcd.* for C<sub>15</sub>H<sub>26</sub>O<sub>2</sub>: 238.1933, *found*: 238.1910.

**Exaltolide (2).** Colorless syrup. <sup>1</sup>H NMR: 1.32 - 1.45 (m, 20H), 1.57 - 1.70 (m, 4H), 2.33 (t, 2H, J = 7.0), 4.14 (t, 2H, J = 5.8). <sup>13</sup>C NMR: 24.9, 25.1, 25.9, 26.0, 26.0, 26.4, 26.7, 26.9, 27.1, 27.2, 27.8, 28.4, 34.4, 63.9, 174.0. IR: 2929, 2858, 1737, 1461, 1349, 1237, 1167, 1108, 1069, 1052, 719. MS *m/z* (rel. intensity): 240 (M<sup>+</sup>, 46), 222 (31), 180 (18), 138 (13), 124 (14), 110 (15), 97 (31), 83 (47), 69 (66), 55 (100). HR-MS *calcd.* for C<sub>15</sub>H<sub>28</sub>O<sub>2</sub>: 240.2089, *found*: 240.2080.

**10-Undecen-1-yl 10-undecenoate (8).** Colorless syrup. <sup>1</sup>H NMR: 1.30 - 1.41 (m, 24H), 1.55 - 1.65 (m, 4H), 1.98 - 2.08 (m, 4H), 2.28 (t, 2H, J = 7.6), 4.06 (t, 2H, J = 6.7), 4.89 - 5.04 (m, 4H), 5.70 - 5.90 (m, 2H). <sup>13</sup>C NMR: 24.6, 25.5, 28.3, 28.5, 28.5, 28.7, 28.7, 28.7, 28.8, 28.9, 29.0, 29.1, 33.4, 34.0, 63.9, 113.7, 113.8, 138.6, 173.4. IR: 3077, 2927, 2855, 1739, 1641, 1465, 1239, 1172, 993, 909, 723. MS *m/z* (rel. intensity): 336 (M<sup>+</sup>, 8), 185 (7), 167 (12), 152 (28), 124 (20), 110 (29), 96 (51), 82 (67), 69 (65), 55 (100).

**10-Eicosen-20-olide (9).** Colorless syrup. Ratio of isomers ~ 45 : 55.  $^1\text{H}$  NMR: 1.23 - 1.45 (m, 22H), 1.58 - 1.68 (m, 4H), 1.98 - 2.03 (m, 4H), 2.31 (t, 2H,  $J = 6.4$ ), 4.11 (td, 2H,  $J = 5.6, 1.7$ ), 5.28 - 5.44 (m, 2H).  $^{13}\text{C}$  NMR: 25.2, 25.9, 26.2, 26.6, 26.7, 27.7, 28.0, 28.4, 28.5, 28.7, 28.7, 28.8, 29.0, 29.0, 29.1, 29.1, 29.2, 29.4, 29.5, 31.7, 32.0, 34.5, 34.8, 64.0, 64.2, 130.0, 130.1, 130.6, 130.9, 173.9, 174.0. IR: 3001, 2926, 2854, 1737, 1462, 1385, 1348, 1252, 1236, 1175, 1117, 1090, 1066, 1030, 969, 722. MS  $m/z$  (rel. intensity): 308 ( $\text{M}^+$ , 32), 290 (11), 124 (18), 110 (23), 96 (74), 82 (100). HR-MS *calcd.* for  $\text{C}_{20}\text{H}_{36}\text{O}_2$ : 308.2715, *found*: 308.2720.

**20-Eicosanolide (7).** Colorless syrup.  $^1\text{H}$  NMR: 1.26 - 1.30 (m, 34H), 2.31 (t, 2H,  $J = 7.0$ ), 4.11 (t, 2H,  $J = 5.9$ ).  $^{13}\text{C}$  NMR (resolved signals): 22.7, 25.1, 26.0, 27.5, 27.6, 27.7, 27.8, 27.9, 28.2, 28.3, 28.4, 28.7, 28.8, 28.9, 29.0, 31.6, 34.7, 64.4, 173.6. IR: 2925, 2854, 1737, 1461, 1351, 1250, 1169, 1112, 808, 722. MS  $m/z$  (rel. intensity): 310 ( $\text{M}^+$ , 75), 292 (40), 250 (11), 124 (12), 111 (23), 97 (47), 83 (57), 69 (65), 55 (100). HR-MS *calcd.* for  $\text{C}_{20}\text{H}_{38}\text{O}_2$ : 310.2872, *found*: 310.2858.

**Dec-9-en-2-yl hex-5-enoate (11).** Colorless syrup;  $^1\text{H}$  NMR: 1.14 (s, 3H), 1.17 (s, 3H), 1.20 - 1.57 (m, 11H), 1.69 (quint., 2H,  $J = 7$ ), 1.90 - 2.10 (m, 4H), 2.24 (t, 2H,  $J = 7$ ), 4.81 - 5.04 (m, 4H), 5.62 - 5.86 (m, 2H).  $^{13}\text{C}$  NMR: 173.1, 138.9, 137.7, 115.2, 114.1, 70.7, 35.8, 33.9, 33.7, 33.0, 29.2, 28.9, 28.7, 25.3, 24.1, 19.9. IR: 3080, 2990, 2920, 2860, 1725, 1645, 1380, 1250, 1180, 1130, 990, 910. MS  $m/z$  (rel. intensity): 252 ( $\text{M}^+$ , 2), 206 (2), 163 (3), 138 (18), 114 (83), 110 (19), 97 (100), 83 (39), 82 (31), 80 (31), 69 (74), 68 (53), 67 (28), 55 (77), 41 (61).

**13-Methyl-tridec-5-en-13-olide (10).** Colorless syrup; (*E*) : (*Z*) ~ 31 : 69.  $^1\text{H}$  NMR: 1.19 - 2.46 (m, 22H), 4.88 - 5.07 (m, 1H), 5.30 - 5.41 (m, 2H).  $^{13}\text{C}$  NMR: (*Z*)-isomer:

20.7, 23.3, 25.0, 25.0, 25.2, 26.2, 26.6, 27.0, 33.8, 34.7, 69.3, 128.9, 130.9, 173.4. (*E*)-isomer: 20.4, 22.5, 24.3, 26.2, 27.1, 27.4, 31.3, 32.2, 32.6, 34.4, 69.7, 129.3, 132.3, 173.6. IR: 3000, 2930, 2857, 1732, 1653, 1460, 1414, 1374, 1345, 1293, 1246, 1206, 1172, 1132, 1107, 1042, 1022, 971, 877, 806, 719. MS *m/z* (rel. intensity): 224 ( $M^+$ , 10), 164 (8), 126 (30), 95 (43), 81 (100), 67 (93), 55 (77).

**(+)-(R)-2-Methyl-hept-6-en-1-yl oct-7-enoate (+)-(15).** Colorless syrup.  $^1\text{H}$  NMR: 0.92 (d, 3H,  $J = 6.8$ ), 1.02 - 1.52 (m, 8H), 1.56 - 1.83 (m, 3H), 1.99 - 2.10 (m, 4H), 2.31 (t, 2H,  $J = 7.3$ ), 3.89 (dd, 1H,  $J = 10.7, 6.6$ ), 3.92 (dd, 1H,  $J = 10.7, 6.0$ ), 4.91 - 5.05 (m, 4H), 5.70 - 5.90 (m, 2H).  $^{13}\text{C}$  NMR: 16.9, 24.9, 26.2, 28.5, 28.6, 32.5, 32.9, 33.6, 33.9, 34.4, 69.1, 114.4, 114.5, 138.7, 138.8, 173.9. IR: 3078, 2932, 2858, 1738, 1641, 1462, 1247, 1172, 994, 911. MS *m/z* (rel. intensity): 252 ( $M^+$ , <1), 210 (2), 125 (19), 110 (23), 95 (23), 81 (47), 69 (97), 55 (100). HR-MS *calcd.* for  $\text{C}_{16}\text{H}_{28}\text{O}_2$ : 252.2089, *found*: 252.2078.  $[\alpha]_{\text{D}}^{23} = +1.42^\circ$ ,  $[\alpha]_{546}^{23} = +1.68^\circ$  ( $c = 16.5$ ,  $\text{CH}_2\text{Cl}_2$ ).

**(+)-(R)-12-Methyl-tridec-7-en-13-olide (+)-(16).** Colorless syrup. (*E*) : (*Z*) ~ 96 : 4.  $^1\text{H}$  NMR (*E*-isomer): 0.89 (d, 3H,  $J = 6.8$ ), 1.18 - 2.11 (m, 15H), 2.30 - 2.37 (m, 2H), 3.81 (dd, 1H,  $J = 10.8, 9.2$ ), 4.06 (dd, 1H,  $J = 10.8, 3.5$ ), 5.24 - 5.29 (m, 2H).  $^{13}\text{C}$  NMR (*E*-isomer): 15.9, 25.1, 25.3, 26.8, 28.1, 30.2, 31.2, 31.5, 32.3, 34.9, 68.4, 131.5, 131.6, 174.0. IR: 3024, 2929, 2856, 1734, 1461, 1444, 1378, 1341, 1252, 1206, 1168, 1148, 1116, 1007, 970, 737. MS *m/z* (rel. intensity): 224 ( $M^+$ , 24), 109 (23), 95 (51), 81 (100), 67 (69). HR-MS *calcd.* for  $\text{C}_{14}\text{H}_{24}\text{O}_2$ : 224.1776, *found*: 224.1755.  $[\alpha]_{\text{D}}^{25} = +31.48^\circ$ ,  $[\alpha]_{546}^{25} = +32.24^\circ$  ( $c = 5.0$ ,  $\text{CH}_2\text{Cl}_2$ ).

**(+)-(R)-12-Methyl-13-tridecanolide (+)-(12)**. Colorless syrup.  $^1\text{H}$  NMR: 0.92 (d, 3H,  $J = 6.9$ ), 1.13 - 1.91 (m, 19 H), 2.26 - 2.50 (m, 2H), 3.70 (dd, 1H,  $J = 10.9, 8.4$ ), 4.20 (dd, 1H,  $J = 10.9, 3.4$ ).  $^{13}\text{C}$  NMR: 16.7, 22.5, 23.7, 24.1, 24.6, 25.6, 25.9, 26.2, 26.3, 30.1, 31.9, 34.2, 68.0, 173.9. IR: 2931, 2861, 1736, 1461, 1447, 1377, 1241, 1150, 1109, 1010, 733. MS  $m/z$  (rel. intensity): 226 ( $\text{M}^+$ , 33), 208 (27), 153 (20), 124 (13), 111 (19), 98 (39), 83 (39), 69 (80), 55 (96), 41 (100). HR-MS *calcd.* for  $\text{C}_{14}\text{H}_{26}\text{O}_2$ : 226.1933, *found*: 226.1920.  $[\alpha]_{\text{D}}^{25} = + 14.54^\circ$ ,  $[\alpha]_{546}^{25} = + 17.22^\circ$  ( $c = 4.25$ ). *ref*<sup>12d</sup>:  $[\alpha]_{\text{D}}^{25} = + 14.7^\circ$ ,  $[\alpha]_{546}^{25} = + 17.5^\circ$  ( $c = 1.4$ ).